For the first time ever, we’re able to reveal vital details about a tumor – including its fundamental phenotype and biological behavior – from just a blood sample,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “This gives healthcare providers the insights they need about a patient’s cancer to make smarter treatment decisions, even when they can’t access tumor tissue for analysis. The novel blood-based approach to comprehensive molecular profiling using our Guardant Infinity Smart Liquid Biopsy platform offers immense potential for future applications in cancer and beyond.”